What the Mount Raymond acquisition means for SLAM Exploration Ltd.’s Goodwin project scale (TSXV: SXL)
Read More 4 minute read Pharma Industry News Lilly’s lepodisiran shows 94% reduction in lipoprotein(a), offering hope for cardiovascular risk management Lilly’s lepodisiran slashed lipoprotein(a) by 94% in a Phase 2 trial. See how this breakthrough could change cardiovascular disease treatment. byPallavi MadhirajuMarch 31, 2025